Item 7.01 Regulation FD Disclosure. Included with this Current Report as Exhibit 99.1 is an updated October 2026 Company Presentation (the “Company Presentation”), which SSi intends to use in communications to shareholders and the investment community.…
Filed Oct 5, 2026Accepted Oct 5, 2026, 8:00 AM EDTCIK 1676163Accession 0001213900-26-106654
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item
7.01 Regulation FD Disclosure.
Included
with this Current Report as Exhibit 99.1 is an updated October 2026 Company Presentation (the “Company Presentation”),
which SSi intends to use in communications to shareholders and the investment community.
The
information set forth in Item 7.01 of this Current Report and in the Company Presentation included as Exhibit 99.1 to this
Current Report, are deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of
that Section. The information set forth in Item 7.01 of this Current Report and in the Company Presentation included as Exhibit
99.1 to this Current Report, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities
Act of 1933, as amended, regardless of any general incorporation language in such filing.
Forward-Looking
Statements
This
Current Report and the Company Presentation included as Exhibit 99.1 to this Current Report that are not historical facts and
are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements
include all statements that are not historical statements of fact and statements regarding the Company’s intent, belief or expectations,
including, but not limited to, product development, clinical and regulatory timelines, market opportunity, competitive position, possible
or assumed future results of operations and other statement that are predictive in nature. The words “anticipate,” “assume,”
“believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,”
“project,” “should,” “could,” “seek,” “designed,” “potential,”
“forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar
expressions to identify such forward-looking statements. These statements relate to future events or SSi’s future financial performance
and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance,
or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied
by these forward-looking statements. You should not place undue reliance on forward-looking statements.